AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Candel Therapeutics Highlights Positive Clinical Progress Across Cancer Immunotherapy Pipeline in Q3 2025
ByAinvest
Thursday, Nov 13, 2025 4:35 pm ET1min read
Candel Therapeutics reported Q3 2025 financial results and highlighted clinical progress across its cancer immunotherapy pipeline. The company presented new Phase 3 subgroup analyses of CAN-2409 in localized prostate cancer and updated survival data from its Phase 1b CAN-3110 trial in recurrent high-grade glioma. Candel plans to submit a Biologics License Application for CAN-2409 in Q4 2026 and initiate a pivotal Phase 3 trial in metastatic non-squamous non-small cell lung cancer in Q2 2026. Net loss for Q3 was $11.3 million, and cash and cash equivalents totaled $87 million as of September 30, 2025.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet